Publications

Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD

Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.

[o.302] Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the icatibant outcome survey, a cohort observational study (4)
[o.309] The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update (4)
[r.128] Disease severity, activity, impact, and control and how to assess them in patients with hereditary angioedema (4)
[r.051] Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives (4)
[o.328] Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the icatibant outcome survey (3)
[o.390] A novel deep intronic SERPING1 variant as a cause of hereditary angioedema due to C1-inhibitor deficiency (3)
[o.340] Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey (2)
[o.404] Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks (2)
[o.426] Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study (2)
[r.186] Expert consensus on prophylactic treatment of hereditary angioedema (1)
[o.141] WAO Guideline for the management of hereditary angioedema (0)
[o.167] Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe (0)
[o.173] Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study (0)
[r.122] Hereditary angioedema with normal C1 inhibitor: Update on evaluation and treatment (0)
[o.179] Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema (0)
[r.186de] Expert consensus on prophylactic treatment of hereditary angioedema (0)
[o.359] Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey (0)
[o.308] The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update (0)
[o.337] Guideline: Hereditary angioedema due to C1 inhibitor deficiency. S1-Guideline of the German Society for Angioedema (DGA), German Society for Internal Medicine (DGIM), German Society for Otorhinolaryngology (DGHNO), German Society for Allergology and Clinical Immunology (DGAKI), German Society for Child and Adolescent Medicine (DGKJ), German Dermatological Society (DDG), German Society for Pediatric Allergology and Environmental Medicine (GPA), German Association of ENT Surgeons (BVHNO) and the German HAE Patient Association (HAE-SHG) (0)
[o.326] Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study (0)

(Last update: 09.2024)

Number of original publications in peer-reviewed journals:	626
Number of reviews in peer-reviewed journals:	221
Number of publications (original work and reviews) in peer-reviewed journals:	847
Cumulative IF for original publications in peer-reviewed journals:	4432.59
Cumulative IF for reviews in peer-reviewed journals:	1648.22
Cumulative IF of publications (original work & reviews) in peer-reviewed journals:	6080.81
Total number of citations: 38,608, h-index: 99 (Web of Science September 2024)	38,608

Download-Information

To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.